PF-07934040

N/A

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NamePF-07934040
Drug Alias NamePF-07934040PF-4040
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesPfizer Investment Co Ltd
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A